Abstract
The recently updated HER2 testing guidelines by ASCO and the College of American Pathologists (CAP) are a significant step towards personalized medicine. It is excellent news that such great effort has been put into standardizing biomarker assessment. Undoubtedly, these recommendations will improve the analytical validity of HER2 testing, its clinical utility and the communication among health-care providers.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Biomarkers, Tumor / genetics*
-
Breast Neoplasms / diagnosis*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / genetics*
-
Breast Neoplasms / pathology
-
Female
-
Genetic Testing / methods*
-
Humans
-
Practice Guidelines as Topic*
-
Precision Medicine / methods*
-
Predictive Value of Tests
-
Prognosis
-
Receptor, ErbB-2 / isolation & purification*
-
Women's Health
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
ERBB2 protein, human
-
Receptor, ErbB-2